NCT03456856View on ClinicalTrials.gov

A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 28, 2017

Primary Completion Date

April 19, 2019

Study Completion Date

May 20, 2019

Conditions
Heart Failure (HF)
Interventions
DRUG

Ivabradine

Film-coated tablets taken orally with food twice a day. Tablets supplied in strengths of 5.0 mg and 7.5 mg. 5.0 tablets were split into equal halves for dosages of 2.5 mg.

Trial Locations (3)

14215

Research Site, Buffalo

19803

Research Site, Wilmington

48202

Research Site, Detroit

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03456856 - A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction. | Biotech Hunter | Biotech Hunter